Advanced search
Publication Cover
Lung Cancer: Targets and Therapy Volume 10, 2019 - Issue
Submit an article Journal homepage
92
Views
2
CrossRef citations to date
0
Altmetric
Original Research

Time To Response In Patients With Advanced Anaplastic Lymphoma Kinase (ALK)-Positive Non-Small-Cell Lung Cancer (NSCLC) Receiving Alectinib In The Phase II NP28673 And NP28761 Studies

Shirish Gadgeel1 Department of Internal Medicine, Division of Hematology and Oncology, The University of Michigan, Ann Arbor, MI48109, USA
,
Alice T Shaw2 Center for Thoracic Cancers, Massachusetts General Hospital, Boston, MA, USA
,
Fabrice Barlesi3 Multidisciplinary Oncology and Therapeutic Innovations Department, Aix-Marseille University, Assistance Publique Hôpitaux de Marseille, Marseille13005, France
,
Lucio Crino4 Department of Medical Oncology, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) Srl I.R.C.C.S., Meldola, FC47014, ItalyORCID Iconhttps://orcid.org/0000-0001-5745-6429
ORCID Icon,
James CH Yang5 National Taiwan University Hospital and National Taiwan University Cancer Centre, Taipei City, TaiwanORCID Iconhttps://orcid.org/0000-0002-5586-5138
ORCID Icon,
Anne-Marie Dingemans6 Department of Pulmonology, Maastricht University Medical Centre, Maastricht6229 HX, The Netherlands
,
Dong-Wan Kim7 Department of Internal Medicine, Seoul National University Hospital, Jongno-Gu, Seoul03080, South Korea
,
Filippo de Marinis8 Division of Thoracic Oncology, European Institute of Oncology IRCCS, Milan20146, ItalyORCID Iconhttps://orcid.org/0000-0002-1118-5536
ORCID Icon,
Mathias Schulz8 Division of Thoracic Oncology, European Institute of Oncology IRCCS, Milan20146, Italy
,
Shiyao Liu9 Genentech Inc., South San Francisco, CA, USA
,
Ravindra Gupta9 Genentech Inc., South San Francisco, CA, USA
,
Vlatka Smoljanovic10 F. Hoffmann-La Roche Ltd., BaselCH-4070, Switzerland
&
Sai-Hong Ignatius Ou11 Division of Hematology-Medical Oncology, Department of Internal Medicine, University of California, Irvine School of Medicine, Orange, CA92617, USACorrespondence[email protected]
 show all
Pages 125-130 | Published online: 13 Nov 2019

Figures & data

Figure 1 TTR in all responders by IRC in the (A) NP28673 study and (B) NP28761 study, and by investigator assessment in the (C) NP28673 study and (D) NP28761 study.

Abbreviations: CI, confidence interval; IRC, independent review committee; TTR, time to response.
Figure 1 TTR in all responders by IRC in the (A) NP28673 study and (B) NP28761 study, and by investigator assessment in the (C) NP28673 study and (D) NP28761 study.

Figure 2 TTCR by IRC in patients with measurable CNS disease at baseline and confirmed CNS responses in the (A) NP28673 study and (B) NP28761 study, and in patients with measurable and/or non-measurable CNS disease at baseline and confirmed CNS responses in the (C) NP28673 study and (D) NP28761 study.

Abbreviations: CI, confidence interval; CNS, central nervous system; IRC, independent review committee; NE, not evaluable; TTCR, time to CNS response.
Figure 2 TTCR by IRC in patients with measurable CNS disease at baseline and confirmed CNS responses in the (A) NP28673 study and (B) NP28761 study, and in patients with measurable and/or non-measurable CNS disease at baseline and confirmed CNS responses in the (C) NP28673 study and (D) NP28761 study.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.